Affluent Medical: Promising results for Epygon in TCT

Affluent Medical presented encouraging preliminary clinical results for its Epygon biomimetic mitral valve at the TCT conference in the United States. Two high-risk patients were treated for severe mitral regurgitation with this innovative valve. According to studies conducted at the Mayo Clinic, Epygon improves cardiac function by preserving the natural blood flow of the left ventricle.

While most prostheses create turbulent flow, Epygon promotes the formation of a physiological diastolic vortex. Results show, in particular, a reduction in mitral regurgitation and a 50% decrease in left ventricular workload three months after implantation.

The device is designed to be implanted transcatheterically, thus avoiding open-heart surgery. The Epygon valve could therefore combine the advantages of reconstructive surgery with a minimally invasive approach.